Navigation Links
Mylan Launches Generic Version of Wellbutrin XL® Tablets
Date:10/1/2010

PITTSBURGH, Oct. 1 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL®.

Bupropion Hydrochloride Extended-release Tablets had U.S. sales of approximately $752 million for the 12 months ending June 30, 2010, according to IMS Health.

Currently, Mylan has 150 ANDAs pending FDA approval representing $94.2 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $21.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
2. Mylan Receives Approval for Generic Version of Prograf® Capsules
3. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
4. Mylan Announces Completion of Add-On Offering of Senior Notes
5. Mylan Announces Pricing of Add-On Offering of Senior Notes
6. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
7. Mylan Announces Settlement Agreement for Namenda®
8. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
9. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
10. Mylan Receives Approval for Nabumetone Tablets
11. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Walmart (NYSE: WMT ) and Eli Lilly and Company ... affordable insulin option for people with diabetes.   , ... Beginning in mid-September, Lilly,s Humulin ® brand of ... name Humulin ® ReliOn ®, including 10 mL vials of Humulin® ...
... NASHVILLE, Tenn. , June 21 Emdeon Inc. (NYSE: ... payment cycle management solutions, today announced the acquisition of Chapin Revenue ... is a leading technology-enabled provider of hospital-based revenue cycle services including ... , , ...
Cached Medicine Technology:Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... growth worsens ovarian cancer, but its production can be stifled ... nanoparticle, a research team led by scientists at The University ... Journal of the National Cancer Institute. , "The protein interleukin-8 ... senior author Anil Sood, M.D., professor in the M. D. ...
... Works to Help Hollywood ,Stay Sane in an Insane ... ... Roy, M.A., "The,Industry Therapist" ( http://www.theIndustryTherapist.com ) is asking the,question why the ... Spears, mental illness., "Heath Ledger,s death is being treated with kid ...
... Feb. 26 Hologic, Inc.,(Nasdaq: HOLX ) today ... at the Raymond James & Associates 29th Annual,Institutional Investors ... Grand Cypress Hotel in Orlando, FL., Interested parties ... of,Hologic,s investor presentation on Monday, March 3, 2008 at ...
... clots, study says, , , TUESDAY, Feb. 26 (HealthDay News) ... associated with cancer treatment-related anemia may do more harm ... , The drugs -- erythropoiesis-stimulating agents (ESAs) -- increase ... risk of blood clots known as venous thromboembolisms (VTE) ...
... Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, Feb. 26 ... one of the leading Mexican,distributors of pharmaceutical products, beauty aids, ... its consolidated financial and operating results for the fourth,quarter of ...
... 26 Schnitzer West announced today,that one of the ... Coast gym in The Shops at The Bravern in ... time to meet the needs of approximately 2,300,Microsoft employees ... of the,project beginning this fall., DavidBartonGym will offer ...
Cached Medicine News:Health News:Researchers identify and shut down protein that fuels ovarian cancer 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 3Health News:Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3
... This unique system uses prolene as thread-guide ... The hollow Ritleng Probe is inserted into the ... fed through it. The probe is then withdrawn ... mm 0.64 mm diam silicone tubing into place. ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... collarette conforms to natural anatomy of ... Pre-loaded on disposable inserter/dilator instrument for ... forceps. The Micro-Large plugs feature the ... natural shape of the eyelid. The ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: